Re-Purposing Drugs for the Treatment of Polycystic Kidney Disease:

Size: px
Start display at page:

Download "Re-Purposing Drugs for the Treatment of Polycystic Kidney Disease:"

Transcription

1 Re-Purposing Drugs for the Treatment of Polycystic Kidney Disease: Partnership with the Polycystic Kidney Disease Foundation PKD Models: pcy and jck Mice, PCK Rat PreClinOmics, Inc. 1

2 PKDF Goals The Accelerating Treatments to Patients (ATP) Initiative A comprehensive, integrated research and development program that represents the core of our work. ATP was launched in 2010 to speed up development of treatments which could slow or stop the progression of PKD. o Scientific Meetings o Tissue Donation o Core Research Grant o Drug Repurposing o PKD Outcomes Consortium o Clinical Trial Awareness Program Each of the programs within ATP is important and interconnected. PreClinOmics chosen as the preferred CRO for colony maintenance and conduct of efficacy studies. 2

3 Rodent Models jck (C57Bl/6J-nek8 jck ): a mouse model of slowly progressing renal cystic disease associated with the same gene that causes human nephronophthisis type 9. Renal cysts in this mouse develop in multiple regions of the nephron and is more severe in male mice. These mice are bred at PreClinOmics. pcy (CD-1-pcy Iusm ): a mouse model of slowly progressive renal cystic disease associated with the same gene that causes human nephronophthisis type 3. Renal cysts in this mouse initially develop in the collecting tubules but other segments of the nephron become cystic as disease progresses. Male and female mice are similarly affected. These mice are bred at PreClinOmics. PCK (PCK/Crl-Pkhd1pck/Crl): a rat model of the slowly progressive form of autosomal recessive PKD with a mutation in the same gene that causes human ARPKD (PKHD1). This model displays significant kidney and liver cyst development similar to most patients with PKD. This allows an evaluation of treatment efficacy for both kidney and liver pathology. (Model maintained at Charles River Labs) There are many models of polycystic kidney disease, but the 3 outlined above have been designated the primary models that the PKDF was interested in pursuing based on their collective translational power. 3

4 General Study Design: jck Mouse Male jck mice 4 weeks of age Body weight and feed intake recorded weekly Test substances are administered for 5 weeks (oral gavage or admixed in the diet) Endpoints measured: Cyst volume and fibrosis in kidney Kidney weight Serum BUN Concentration of test article in blood Other analyses relevant to cellular mechanism may be included 4

5 Reference Compound Validation: jck Mouse Based on published literature and preliminary in-house work, the CDK inhibitor, roscovitine, was selected as the positive control for all studies in jck mice Representative cumulative data obtained with roscovitine in this model are shown below: Renal cyst vol (%BW) * t-test p<0.05 * vehicle Roscovitine 150 mg/kg/day Roscovitine elicited a significant reduction in renal cyst volume compared to vehicle in jck mice 5

6 Study Design: pcy Mouse Male pcy mice 4 weeks of age Body weight and feed intake recorded weekly Test substances are administered for 10 weeks (admixed in the diet) Endpoints measured: Cyst volume and fibrosis in kidney Kidney weight Serum BUN Concentration of test article in blood Other analyses relevant to target may be included 6

7 R e n a l c y s t v o lu m e (% B W ) Reference Compound Validation: pcy Mice Based on published literature and preliminary in-house work, the vasopressin antagonist, tolvaptan, was selected as the positive control for all studies in pcy mice. Representative cumulative data obtained with tolvaptan in this model are shown below: 4 3 * t-te s t p < * V e h ic le T o lv a p ta n m g /k g /d a y Tolvaptan significantly reduced renal cyst volume compared to vehicle in pcy mice. 7

8 General Study Design: PCK Rat Male PCK rats 4 weeks of age Body weight and feed intake recorded weekly Compound administered for 12 weeks (oral gavage or admixed in the diet) Endpoints measured: Cyst volume and fibrosis in kidney and liver Kidney and liver weight Serum BUN, ALT, AST, Bilirubin Concentration of test substance in blood Other analyses relevant to cellular mechanism may be included 8

9 R e n a l c y s t v o l (% B W ) Reference Compound Validation: PCK Rat Based on published literature, the PPARγ agonist, pioglitazone, was selected as the positive control for all studies in PCK rat While measures of renal function are included in the study, the primary endpoint is cyst volume quantification by histology Representative cumulative data obtained with pioglitazone in this model are shown below: * p < 0.0 5, t-te s t * V e h ic le P io g lita z o n e 2 0 m g /k g Pioglitazone induces a significant reduction in renal cyst volume compared to vehicle in PCK rats 9

Cystic Renal Disease, for USMLE Step One. Howard J. Sachs, MD

Cystic Renal Disease, for USMLE Step One. Howard J. Sachs, MD Cystic Renal Disease, for USMLE Step One Howard J. Sachs, MD www.12daysinmarch.com The Major Players Medullary Sponge Kidney (MSK) Polycystic Kidney Disease (PKD) Autosomal Recessive: Childhood Autosomal

More information

Renal Cystic Disease. Dr H Bierman

Renal Cystic Disease. Dr H Bierman Renal Cystic Disease Dr H Bierman Objectives Be able to diagnose renal cystic disease Genetic / non-genetic Be able to describe patterns of various renal cystic disease on routine imaging studies Be able

More information

New Treatments for ADPKD how close are we?

New Treatments for ADPKD how close are we? New Treatments for ADPKD how close are we? Leicester General Hospital 28 Jan 2012 Professor Albert Ong a.ong@sheffield.ac.uk The cystic degeneration of the kidneys, once it reaches the point where it can

More information

microrna Therapeutics Harnessing the power of micrornas to target multiple pathways of disease

microrna Therapeutics Harnessing the power of micrornas to target multiple pathways of disease microrna Therapeutics Harnessing the power of micrornas to target multiple pathways of disease January 2018 Safe Harbor Statement Statements contained in this presentation regarding matters that are not

More information

Report on the Deliberation Results

Report on the Deliberation Results Report on the Deliberation Results March 3, 2014 Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare [Brand name] (a) Samsca Tablets 7.5 mg (b)

More information

Autosomal Dominant Polycystic Kidney Disease. Dr. Sameena Iqbal Nephrologist CIUSSS West Island

Autosomal Dominant Polycystic Kidney Disease. Dr. Sameena Iqbal Nephrologist CIUSSS West Island Autosomal Dominant Polycystic Kidney Disease Dr. Sameena Iqbal Nephrologist CIUSSS West Island Disclosure Honorarium for Consulting on the Reprise trial from Otsuka Mayo clinic preceptorship for PKD with

More information

Tubulointerstitial Renal Disease. Anna Vinnikova, MD Division of Nephrology

Tubulointerstitial Renal Disease. Anna Vinnikova, MD Division of Nephrology Tubulointerstitial Renal Disease Anna Vinnikova, MD Division of Nephrology Part I: Cystic Renal Disease www.pathguy.com Simple cysts Simple cysts May be multiple Usually 1 5cm, may be bigger Translucent,

More information

Late progression of renal pathology and cyst enlargement is reduced by rapamycin in a mouse model of nephronophthisis

Late progression of renal pathology and cyst enlargement is reduced by rapamycin in a mouse model of nephronophthisis original article http://www.kidney-international.org & 29 International Society of Nephrology Late progression of renal pathology and cyst enlargement is reduced by rapamycin in a mouse model of nephronophthisis

More information

Delaying Progression of Renal Complications of Autosomal Dominant Polycystic Kidney Disease by Tolvaptan Inhibition of Arginine Vasopressin

Delaying Progression of Renal Complications of Autosomal Dominant Polycystic Kidney Disease by Tolvaptan Inhibition of Arginine Vasopressin Delaying Progression of Renal Complications of Autosomal Dominant Polycystic Kidney Disease by Tolvaptan Inhibition of Arginine Vasopressin Briefing Document for 5 August 2013 Advisory Committee Meeting

More information

Supplemental Figure 1. Western blot analysis indicated that MIF was detected in the fractions of

Supplemental Figure 1. Western blot analysis indicated that MIF was detected in the fractions of Supplemental Figure Legends Supplemental Figure 1. Western blot analysis indicated that was detected in the fractions of plasma membrane and cytosol but not in nuclear fraction isolated from Pkd1 null

More information

Nephrology Grand Rounds. Vasishta Tatapudi, MD January 24 th, 2013

Nephrology Grand Rounds. Vasishta Tatapudi, MD January 24 th, 2013 Nephrology Grand Rounds Vasishta Tatapudi, MD January 24 th, 2013 Case Summary Chief complaint: A twenty-six year old African American female veteran presented to ER with left flank pain for two days.

More information

Research Introduction

Research Introduction Research Introduction 9.17.13 Altered metabolism in polycystic kidney disease Telomerase activity in polycystic kidney disease cells Autosomal dominant polycystic kidney disease ADPKD is the most common

More information

Shuma Hirashio 1,2, Shigehiro Doi 1 and Takao Masaki 1*

Shuma Hirashio 1,2, Shigehiro Doi 1 and Takao Masaki 1* Hirashio et al. Renal Replacement Therapy (2018) 4:24 https://doi.org/10.1186/s41100-018-0164-9 CASE REPORT Open Access Magnetic resonance imaging is effective for evaluating the therapeutic effect of

More information

CYSTIC DISEASES of THE KIDNEY. Dr. Nisreen Abu Shahin

CYSTIC DISEASES of THE KIDNEY. Dr. Nisreen Abu Shahin CYSTIC DISEASES of THE KIDNEY Dr. Nisreen Abu Shahin 1 Types of cysts 1-Simple Cysts 2-Dialysis-associated acquired cysts 3-Autosomal Dominant (Adult) Polycystic Kidney Disease 4-Autosomal Recessive (Childhood)

More information

SUISSE ADPKD Cohort Treatment and Outcomes with Tolvaptan, first in class Vasopressin V2 Antagonist. Hirslanden, 22 March 2018 Stefan Russmann

SUISSE ADPKD Cohort Treatment and Outcomes with Tolvaptan, first in class Vasopressin V2 Antagonist. Hirslanden, 22 March 2018 Stefan Russmann SUISSE ADPKD Cohort Treatment and Outcomes with Tolvaptan, first in class Vasopressin V2 Antagonist Hirslanden, 22 March 2018 Stefan Russmann 4 th of July 2004 Database development with outcomes and safety

More information

Genetic causes 90% Other causes 10% No variants are found in known genes associated with ADPKD

Genetic causes 90% Other causes 10% No variants are found in known genes associated with ADPKD CLINICIAN PRODUCT SHEET Genome.One Polycystic Kidney Disease Test Genome.One offers a diagnostic genetic test for patients with polycystic kidney disease (PKD), with a focus on the most common form, autosomal

More information

New therapeutic prospects in autosoma dominant polycystic kidney disease

New therapeutic prospects in autosoma dominant polycystic kidney disease http://www.senefro.org 2008 Órgano Oficial de la Sociedad Española de Nefrología short reviews New therapeutic prospects in autosoma dominant polycystic kidney disease Roser Torra Enfermedades Renales

More information

UAB P30 CORE A: The Hepato-Renal Fibrocystic Diseases Translational Resource

UAB P30 CORE A: The Hepato-Renal Fibrocystic Diseases Translational Resource PKD Foundation UAB P30 CORE A: The Hepato-Renal Fibrocystic Diseases Translational Resource http://www.arpkdstudies.uab.edu/ Director: Co-Director: Lisa M. Guay-Woodford, MD William E. Grizzle, MD, PhD

More information

Dr. Najla a Aldaoud. Omar Ayman Khasawneh

Dr. Najla a Aldaoud. Omar Ayman Khasawneh Pathology 1 Congenital & Cystic diseases of the kidney Dr. Najla a Aldaoud Omar Ayman Khasawneh 1 P a g e Slides are included بسم هللا الرحمن الرحيم Today is our first pathology lectures, Dr Najla' will

More information

Yun-Jung Choi, Jiangao Song, Jeff D. Johnson, Charles McWherter. NASH-TAG Conference Park City, Utah January 4, 2019

Yun-Jung Choi, Jiangao Song, Jeff D. Johnson, Charles McWherter. NASH-TAG Conference Park City, Utah January 4, 2019 Combination Therapy of Seladelpar and Liraglutide Attenuates Obesity, Hepatic Steatosis and Fibrosis in a Diet-induced and Biopsy-confirmed Mouse Model of NASH Yun-Jung Choi, Jiangao Song, Jeff D. Johnson,

More information

Groningen PKD Expertise Center. Groningen PKD Expertise Center. Groningen PKD Expertise Center. Groningen PKD Expertise Center

Groningen PKD Expertise Center. Groningen PKD Expertise Center. Groningen PKD Expertise Center. Groningen PKD Expertise Center Human polycystic kidney disease. From evolving therapies towards clinical use Prof.dr. Ron T. Gansevoort Chair PKD Expertise Center University Medical Center Groningen The Netherlands Conflict of Interest

More information

Genetic Identification of Two Major Modifier Loci of Polycystic Kidney Disease Progression in pcy Mice

Genetic Identification of Two Major Modifier Loci of Polycystic Kidney Disease Progression in pcy Mice Genetic Identification of Two Major Modifier Loci of Polycystic Kidney Disease Progression in pcy Mice David D.L. Woo, Diana K.P. Nguyen, Niloofar Khatibi, and Pamela Olsen Department of Medicine, UCLA

More information

3 generations of ADPKD. 1 long-awaited treatment.

3 generations of ADPKD. 1 long-awaited treatment. 3 generations of ADPKD. 1 long-awaited treatment. HOPE is finally here now that treatment is available for people with autosomal dominant polycystic kidney disease (ADPKD). JYNARQUE is proven to slow kidney

More information

Genetic Diseases Of The Kidney READ ONLINE

Genetic Diseases Of The Kidney READ ONLINE Genetic Diseases Of The Kidney READ ONLINE Genetic Diseases of the Kidney offers expert insight into the role of genetic abnormalities in the pathogenesis of abnormal kidney function and kidney disease.

More information

SMC briefing note. The following medicines were accepted for use: Contact details. About SMC. Media contact. Number 98 January 2016

SMC briefing note. The following medicines were accepted for use: Contact details. About SMC. Media contact. Number 98 January 2016 Monthly briefings are produced in order to help members of the media and other interested people understand the work and advice of the Scottish Medicines Consortium. The detailed advice for each medicine

More information

Advanced Concept of Nursing- II UNIT-VI Advance Nursing Management of Genitourinary (GU) Diseases.

Advanced Concept of Nursing- II UNIT-VI Advance Nursing Management of Genitourinary (GU) Diseases. In The Name of God (A PROJECT OF NEW LIFE COLLEGE OF NURSING KARACHI) Advanced Concept of Nursing- II UNIT-VI Advance Nursing Management of Genitourinary (GU) Diseases. Shahzad Bashir RN, BScN, DCHN,MScN

More information

Patient Survey of current water Intake practices in autosomal dominant Polycystic kidney disease: the SIPs survey

Patient Survey of current water Intake practices in autosomal dominant Polycystic kidney disease: the SIPs survey Clinical Kidney Journal, 2017, 1 5 doi: 10.1093/ckj/sfw153 Original Article ORIGINAL ARTICLE Patient Survey of current water Intake practices in autosomal dominant Polycystic kidney disease: the SIPs survey

More information

Cost-effectiveness of tolvaptan (Jinarc ) for the treatment of autosomal dominant polycystic kidney disease (ADPKD)

Cost-effectiveness of tolvaptan (Jinarc ) for the treatment of autosomal dominant polycystic kidney disease (ADPKD) Cost-effectiveness of tolvaptan (Jinarc ) for the treatment of autosomal dominant polycystic kidney disease (ADPKD) The NCPE has issued a recommendation regarding the cost-effectiveness of tolvaptan (Jinarc

More information

ET E H S T C A F NT IE T A P

ET E H S T C A F NT IE T A P PATIENT FACT SHEET Genetic Testing for Polycystic Kidney Disease What is polycystic kidney disease? Polycystic kidney disease (PKD) is a rare inherited condition in which many fluid-filled sacs (cysts)

More information

Role of interstitial inflammation in the pathogenesis of polycystic kidney disease

Role of interstitial inflammation in the pathogenesis of polycystic kidney disease bs_bs_banner Nephrology 18 (2013) 317 330 Review Article Role of interstitial inflammation in the pathogenesis of polycystic kidney disease MICHELLE HT TA, DAVID CH HARRIS and GOPALA K RANGAN Centre for

More information

Prag. Polycystic kidney disease: ARPKD & ADPKD. Max Christoph Liebau

Prag. Polycystic kidney disease: ARPKD & ADPKD. Max Christoph Liebau Prag Polycystic kidney disease: ARPKD & ADPKD Max Christoph Liebau Department of Pediatrics and Center for Molecular Medicine, University Hospital of Cologne Glasgow, 06th of September 2017 Cystic kidney

More information

Inhibition of Cdc25A Suppresses Hepato-renal Cystogenesis in Rodent Models of Polycystic Kidney and Liver Disease

Inhibition of Cdc25A Suppresses Hepato-renal Cystogenesis in Rodent Models of Polycystic Kidney and Liver Disease GASTROENTEROLOGY 2012;142:622 633 Inhibition of Cdc25A Suppresses Hepato-renal Cystogenesis in Rodent Models of Polycystic Kidney and Liver Disease TATYANA V. MASYUK,* BRYNN N. RADTKE,* ANGELA J. STROOPE,*

More information

ADPKD, what have the last 10 years taught us? Arlene B. Chapman MD Professor of Medicine Director, Section of Nephrology University of Chicago

ADPKD, what have the last 10 years taught us? Arlene B. Chapman MD Professor of Medicine Director, Section of Nephrology University of Chicago 2016 ADPKD, what have the last 10 years taught us? Arlene B. Chapman MD Professor of Medicine Director, Section of Nephrology University of Chicago 2016 Can we TRUMP the cysts? Disclosures Consultant for

More information

Triptolide reduces cyst formation in a neonatal to adult transition Pkd1 model of ADPKD

Triptolide reduces cyst formation in a neonatal to adult transition Pkd1 model of ADPKD Nephrol Dial Transplant (2010) 1 of 8 doi: 10.1093/ndt/gfp777 NDT Advance Access published February 4, 2010 Original Article Triptolide reduces cyst formation in a neonatal to adult transition Pkd1 model

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AD Award Number: W81XWH-12-1-0528 TITLE: INTRAVENOUS RENAL CELL TRANSPLANTATION FOR POLYCYSTIC KIDNEY DISEASE PRINCIPAL INVESTIGATOR: JESUS DOMINGUEZ, M.D. CONTRACTING ORGANIZATION: Indiana University

More information

IMPURITIES: GUIDELINE FOR RESIDUAL SOLVENTS PDE FOR CUMENE

IMPURITIES: GUIDELINE FOR RESIDUAL SOLVENTS PDE FOR CUMENE INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE DRAFT CONSENSUS GUIDELINE IMPURITIES: GUIDELINE FOR RESIDUAL SOLVENTS Released for

More information

Clinical and Pathologic Findings in Two New Allelic Murine Models of Polycystic Kidney Disease

Clinical and Pathologic Findings in Two New Allelic Murine Models of Polycystic Kidney Disease J Am Soc Nephrol 10: 2534 2539, 1999 Clinical and Pathologic Findings in Two New Allelic Murine Models of Polycystic Kidney Disease CAROLE VOGLER,* SHARON HOMAN, ALETHA PUNG, CONSTANCE THORPE,* JANE BARKER,

More information

Polycystic kidney diseases: From molecular discoveries to targeted therapeutic strategies

Polycystic kidney diseases: From molecular discoveries to targeted therapeutic strategies Cell. Mol. Life Sci. 65 (2008) 605 619 1420-682X/08/040605-15 DOI 10.1007/s00018-007-7362-x Birkhäuser Verlag, Basel, 2007 Cellular and Molecular Life Sciences Biomedicine & Diseases: Review Polycystic

More information

Genetics in Pediatric Nephrology. S Alexander J Fletcher Children s Hospital at Westmead National Kidney Transplant Institute

Genetics in Pediatric Nephrology. S Alexander J Fletcher Children s Hospital at Westmead National Kidney Transplant Institute Genetics in Pediatric Nephrology S Alexander J Fletcher Children s Hospital at Westmead National Kidney Transplant Institute OBJECTIVES 1 2 3 To understand the basis of inheritance of genetic diseases

More information

NIH Public Access Author Manuscript Curr Opin Nephrol Hypertens. Author manuscript; available in PMC 2010 March 1.

NIH Public Access Author Manuscript Curr Opin Nephrol Hypertens. Author manuscript; available in PMC 2010 March 1. NIH Public Access Author Manuscript Published in final edited form as: Curr Opin Nephrol Hypertens. 2009 March ; 18(2): 99. doi:10.1097/mnh.0b013e3283262ab0. Advances in the Pathogenesis and Treatment

More information

Medical intervention: The Tempo study

Medical intervention: The Tempo study ACTUALITÉS NÉPHROLOGIQUES JEAN HAMBURGER HÔPITAL NECKER Medical intervention: The Tempo study Vicente E. Torres Mayo Clinic, Rochester MN PKD (XVI-XIX Centuries) Stefan Bathory, 1588 Galeazzi 1757 Cruveilhier

More information

Corporate Presentation

Corporate Presentation Corporate Presentation November 2016 Kadmon Holdings, Inc. 1 Forward-looking Statement This presentation contains forward looking statements that are based on the beliefs and assumptions and on information

More information

Kidney Disease Research

Kidney Disease Research Thomas Weimbs Assistant Professor, Department of Molecular, Cellular & Developmental Biology Kidney Disease Research The mtor pathway is regulated by polycystin 1, and its inhibition reverses renal cystogenesis

More information

Liver Disease in ADPKD

Liver Disease in ADPKD Liver Disease in ADPKD The information contained in this presentation is the property of the PKD Foundation and to be used for individual informational purposes only. No part of this presentation is to

More information

BIOACTIVE RENAL CELLS AUGMENT KIDNEY FUNCTION IN A RODENT MODEL OF CHRONIC KIDNEY DISEASE

BIOACTIVE RENAL CELLS AUGMENT KIDNEY FUNCTION IN A RODENT MODEL OF CHRONIC KIDNEY DISEASE BIOACTIVE RENAL CELLS AUGMENT KIDNEY FUNCTION IN A RODENT MODEL OF CHRONIC KIDNEY DISEASE Rusty Kelley, PhD Regenerative Medicine & Biology Tengion Labs May 24, 2010 ISCT Annual Meeting, Philadelphia PA

More information

Samsca. Samsca (tolvaptan) Description

Samsca. Samsca (tolvaptan) Description Subject: Samsca Page: 1 of 5 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Last Review Date: September 20, 2018 Samsca Description Samsca (tolvaptan)

More information

Tolvaptan: Slowing Progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Tolvaptan: Slowing Progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Tolvaptan: Slowing Progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Cardiovascular and Renal Drugs Advisory Committee August 5, 2013 Introduction Robert McQuade, PhD Executive Vice President

More information

Lab Activity Report: Mendelian Genetics - Genetic Disorders

Lab Activity Report: Mendelian Genetics - Genetic Disorders Name Date Period Lab Activity Report: Mendelian Genetics - Genetic Disorders Background: Sometimes genetic disorders are caused by mutations to normal genes. When the mutation has been in the population

More information

ADPedKD: detailed description of data which will be collected in this registry

ADPedKD: detailed description of data which will be collected in this registry ADPedKD: detailed description of data which will be collected in this registry I. Basic data 1. Patient ID: will be given automatically 2. Personal information - Date of informed consent: DD/MM/YYYY -

More information

Beverly A. Teicher, PhD DCTD/NCI. The content reflects my professional opinions, not an NCI policy statement.

Beverly A. Teicher, PhD DCTD/NCI. The content reflects my professional opinions, not an NCI policy statement. Beverly A. Teicher, PhD DCTD/NCI The content reflects my professional opinions, not an NCI policy statement. Outline 1. Transplantable Syngeneic Tumors 2. Human Tumor Xenografts 3. Disseminated Disease

More information

Congenital Disorders of the Canine and Feline Biliary Tree

Congenital Disorders of the Canine and Feline Biliary Tree Congenital Disorders of the Canine and Feline Biliary Tree John M. Cullen VMD PhD DACVP FIATP 1 Annual Seminar of the French Society of Veterinary Pathology 2 Embryonic Liver 3 Cytokeratin 7 Ductal Plate

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Polycystic Kidney Disease, Autosomal Dominant OMIM number for disease 173900 Disease

More information

A new Rag2/Il2rg SCID rat. Enabling cell line xenografts. Accelerating PDX establishment. Humanizing the immune system

A new Rag2/Il2rg SCID rat. Enabling cell line xenografts. Accelerating PDX establishment. Humanizing the immune system A new Rag2/Il2rg SCID rat Enabling cell line xenografts Accelerating PDX establishment Humanizing the immune system Tseten Yeshi, Ph.D. VP R&D services@herabiolabs.com 859-414-0648 About Hera BioLabs SRG

More information

Polycystic Kidney Disease:The Cyst-ematic Destruction of Renal Function

Polycystic Kidney Disease:The Cyst-ematic Destruction of Renal Function Eukaryon Volume 5 Celebrating Darwin's 100th Anniversary Article 26 3-25-2009 Polycystic Kidney Disease:The Cyst-ematic Destruction of Renal Function Sadaf Ahmad Ray Choi Quincy Roberts Ben Simpson Jennillee

More information

Genetics Mutations 2 Teacher s Guide

Genetics Mutations 2 Teacher s Guide Genetics Mutations 2 Teacher s Guide 1.0 Summary Mutations II is an extension activity, which reviews and enhances the previous Core activities. We recommend that it follow Mutations and X-Linkage. This

More information

Inhibition of the p38 MAPK pathway ameliorates renal fibrosis in an NPHP2 mouse model

Inhibition of the p38 MAPK pathway ameliorates renal fibrosis in an NPHP2 mouse model Nephrol Dial Transplant (2012) 27: 1351 1358 doi: 10.1093/ndt/gfr550 Advance Access publication 9 November 2011 Inhibition of the p38 MAPK pathway ameliorates renal fibrosis in an NPHP2 mouse model Noriyuki

More information

GU Ultrasound in First Trimester

GU Ultrasound in First Trimester Fetal Renal Malformations: The Role of Ultrasound in Diagnosis & Management Outline 1. Renal Anomalies Urinary Tract Dilation Aberrant Early Development Defects Terminal Maturation Alfred Abuhamad, M.D.

More information

2 nd ARPKD Family Information Day Saturday 6 th July Welcome!

2 nd ARPKD Family Information Day Saturday 6 th July Welcome! 2 nd ARPKD Family Information Day Saturday 6 th July 2013 Welcome! Programme - morning Welcome - Tess Harris, Chief Executive PKD Charity Overview of ARPKD and Programme Dr Larissa Kerecuk, Consultant

More information

Institutional Animal Care and Use Committee (IACUC) Policy on Food and Fluid Regulation in Rodents

Institutional Animal Care and Use Committee (IACUC) Policy on Food and Fluid Regulation in Rodents Institutional Animal Care and Use Committee (IACUC) Policy on Food and Fluid Regulation in Rodents Date of IACUC Review and Approval: June 2, 2017 I. Purpose: The Brown University IACUC recognizes that

More information

Cystic Renal Disease of Childhood

Cystic Renal Disease of Childhood Acta Radiológica Portuguesa, Vol.XIX, nº 74, pág. 90-107, Abr.-Jun., 2007 Cystic Renal Disease of Childhood Ellen Chung Armed Forces Institute of Pathology Terminology Cyst Polycystic kidney disease ARPKD

More information

Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease

Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease Li Chen,, Jared J. Grantham, Xiaogang Li J Clin Invest. 2015;125(6):2399-2412. https://doi.org/10.1172/jci80467.

More information

EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats

EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats Kidney International, Vol. 64 (2003), pp. 1573 1579 EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats VICENTE E. TORRES, WILLIAM E. SWEENEY, JR., XIAOFANG WANG,

More information

Volume 15 - Issue 3, Cover Story

Volume 15 - Issue 3, Cover Story Volume 15 - Issue 3, 2015 - Cover Story ADPKD: Realising Progress Through Patient Empowerment Dr. Richard Sandford, PhD, FRCP ******@***medschl.cam.ac.uk Consultant Clinical Geneticist - Addenbrooke s

More information

Regents of the University of Colorado Aurora, CO 80045

Regents of the University of Colorado Aurora, CO 80045 AWARD NUMBER: W81XWH-16-1-0172 TITLE: Novel mtorc1 and 2 Signaling Pathways in Polycystic Kidney Disease (PKD) PRINCIPAL INVESTIGATOR: Charles L. Edelstein MD, PhD CONTRACTING ORGANIZATION: Regents of

More information

A Primer to Cystic Kidney Diseases and Ciliopathies

A Primer to Cystic Kidney Diseases and Ciliopathies A Primer to Cystic Kidney Diseases and Ciliopathies ERKNet Webinar Max Liebau 04.09.2018 Liebau Pediatric Nephrology, Center for chronically ill children, Center for Molecular Medicine WG CAKUT and Ciliopathies

More information

Males- Western Diet WT KO Age (wks) Females- Western Diet WT KO Age (wks)

Males- Western Diet WT KO Age (wks) Females- Western Diet WT KO Age (wks) Relative Arv1 mrna Adrenal 33.48 +/- 6.2 Skeletal Muscle 22.4 +/- 4.93 Liver 6.41 +/- 1.48 Heart 5.1 +/- 2.3 Brain 4.98 +/- 2.11 Ovary 4.68 +/- 2.21 Kidney 3.98 +/-.39 Lung 2.15 +/-.6 Inguinal Subcutaneous

More information

Kidney Disorders. Renal cysts. Policystic Kidney Diseases. Cystic Renal Dysplasia. Autosomal-Dominant (Adult) Polycystic

Kidney Disorders. Renal cysts. Policystic Kidney Diseases. Cystic Renal Dysplasia. Autosomal-Dominant (Adult) Polycystic Policystic Kidney Diseases Kidney Disorders CONGENITAL CYSTIC GLOMERULAR TUBULES/INTERSTITIUM BLOOD VESSELS OBSTRUCTION TUMORS Lecture : Genito-urinary system. 11 08 2010. Renal cysts Cystic Renal Dysplasia

More information

RaDaR Newsletter. Issue Four, Winter 2016

RaDaR Newsletter. Issue Four, Winter 2016 RaDaR Newsletter Issue Four, Winter 2016 The National Registry of Rare Kidney Diseases (RaDaR) is a Renal Association initiative designed to pull together information from patients with certain rare kidney

More information

Cystinosis Research Foundation Progress Report. Energy homeostasis and muscle wasting in nephropathic cystinosis. Final Report

Cystinosis Research Foundation Progress Report. Energy homeostasis and muscle wasting in nephropathic cystinosis. Final Report Cystinosis Research Foundation Progress Report Energy homeostasis and muscle wasting in nephropathic cystinosis Principle Investigator: Robert Mak, MD, PhD Institution: University of California, San Diego

More information

Nephrology Case Presentation for PCKD. Douglas A. Stahura 24 January 2002 With update 2018

Nephrology Case Presentation for PCKD. Douglas A. Stahura 24 January 2002 With update 2018 Nephrology Case Presentation for PCKD Douglas A. Stahura 24 January 2002 With update 2018 Case Presentation l 48 y/o WM presents with back pain Sharp, over L side/ribs Intermittent but severe 8/10 No radiation

More information

NIH Public Access Author Manuscript Expert Opin Investig Drugs. Author manuscript; available in PMC 2010 April 28.

NIH Public Access Author Manuscript Expert Opin Investig Drugs. Author manuscript; available in PMC 2010 April 28. NIH Public Access Author Manuscript Published in final edited form as: Expert Opin Investig Drugs. 2010 March ; 19(3): 315 328. doi:10.1517/13543781003588491. Novel targets for the treatment of autosomal

More information

Nutrition and Foods Safety Agency of the Centre for Disease Prevention and Control, People s Republic of China. Testing Report

Nutrition and Foods Safety Agency of the Centre for Disease Prevention and Control, People s Republic of China. Testing Report Ministry Health approved Natural Health Products Testing Agency Issued by: Public Health Inspections, Ministry Health (1996) Publication # 53 Nutrition and Foods Safety Agency the Centre for Disease Prevention

More information

Radiological and pathologic findings of fetal renal cystic diseases and associated fetal syndromes: A pictorial review

Radiological and pathologic findings of fetal renal cystic diseases and associated fetal syndromes: A pictorial review Radiological and pathologic findings of fetal renal cystic diseases and associated fetal syndromes: A pictorial review Poster No.: C-2835 Congress: ECR 2010 Type: Educational Exhibit Topic: Pediatric Authors:

More information

Technology appraisal guidance Published: 28 October 2015 nice.org.uk/guidance/ta358

Technology appraisal guidance Published: 28 October 2015 nice.org.uk/guidance/ta358 Tolvaptan for treating autosomal dominant polycystic kidney disease Technology appraisal guidance Published: 28 October 2015 nice.org.uk/guidance/ta358 NICE 2017. All rights reserved. Subject to Notice

More information

Autosomal dominant polycystic kidney disease (AD-

Autosomal dominant polycystic kidney disease (AD- A Pilot Clinical Study to Evaluate Changes in Urine Osmolality and Urine camp in Response to Acute and Chronic Water Loading in Autosomal Dominant Polycystic Kidney Disease Irina Barash,* Manish P. Ponda,*

More information

Tolvaptan for treating autosomal dominant polycystic kidney disease

Tolvaptan for treating autosomal dominant polycystic kidney disease in collaboration with: ERRATUM TO Tolvaptan for treating autosomal dominant polycystic kidney disease 1. The word ********* has been marked as commercial in confidence. a. Section 1.4 (page 13): Hence,

More information

renoprotection therapy goals 208, 209

renoprotection therapy goals 208, 209 Subject Index Aldosterone, plasminogen activator inhibitor-1 induction 163, 164, 168 Aminopeptidases angiotensin II processing 64 66, 214 diabetic expression 214, 215 Angiotensin I intrarenal compartmentalization

More information

Figure S1 Genetic or pharmacologic COX-2 inhibition led to increased kidney

Figure S1 Genetic or pharmacologic COX-2 inhibition led to increased kidney SUPPLEMENTAL FIGURE LEGENDS Figure S1 Genetic or pharmacologic COX-2 inhibition led to increased kidney macrophage infiltration. Wild type or COX-2 -/- mice (2 months old, C57/Bl6 background) were treated

More information

Cellular pathophysiology of cystic kidney disease: insight into future therapies

Cellular pathophysiology of cystic kidney disease: insight into future therapies Int. J. Dev. Biol. 43: 457-461 (1999) Cellular pathophysiology of cystic kidney desease 457 Cellular pathophysiology of cystic kidney disease: insight into future therapies ELLIS D. AVNER*, RICHARD P.

More information

tolvaptan 15mg, 30mg, 45mg, 60mg and 90mg tablets (Jinarc ) Otsuka Pharmaceuticals (UK) Ltd SMC No. (1114/15)

tolvaptan 15mg, 30mg, 45mg, 60mg and 90mg tablets (Jinarc ) Otsuka Pharmaceuticals (UK) Ltd SMC No. (1114/15) tolvaptan 15mg, 30mg, 45mg, 60mg and 90mg tablets (Jinarc ) Otsuka Pharmaceuticals (UK) Ltd SMC No. (1114/15) 04 December 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the

More information

Double inhibition of camp and mtor signalling may potentiate the reduction of cell growth in ADPKD cells

Double inhibition of camp and mtor signalling may potentiate the reduction of cell growth in ADPKD cells Clin Exp Nephrol (2017) 21:203 211 DOI 10.1007/s10157-016-1289-1 ORIGINAL ARTICLE Double inhibition of camp and mtor signalling may potentiate the reduction of cell growth in ADPKD cells Lucia de Stephanis

More information

Vasopressin Antagonists in Polycystic Kidney Disease. Vicente E. Torres, MD

Vasopressin Antagonists in Polycystic Kidney Disease. Vicente E. Torres, MD Vasopressin Antagonists in Polycystic Kidney Disease Vicente E. Torres, MD Summary: Increased cell proliferation and fluid secretion, probably driven by alterations in intracellular calcium homeostasis

More information

AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE 12 th Annual Southwest Nephrology Conference Saturday, Feb 5 th 2011. Update in PKD Marie C. Hogan M.D. Ph.D. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN Disclosures: Research support:

More information

Inhibition of mtor with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD)

Inhibition of mtor with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD) Nephrol Dial Transplant (26) 21: 598 64 doi:1.193/ndt/gfi181 Advance Access publication 11 October 25 Original Article Inhibition of mtor with sirolimus slows disease progression in Han:SPRD rats with

More information

MRC-Holland MLPA. Description version 08; 30 March 2015

MRC-Holland MLPA. Description version 08; 30 March 2015 SALSA MLPA probemix P351-C1 / P352-D1 PKD1-PKD2 P351-C1 lot C1-0914: as compared to the previous version B2 lot B2-0511 one target probe has been removed and three reference probes have been replaced.

More information

ALKA VITA DIABETES TEST

ALKA VITA DIABETES TEST ALKA VITA DIABETES TEST By PCO PreCleanOmics Indianapolis, Indiana Study Number: 4-29-1 11 Aug - 21 Sep Date of Study: 24 Animals Used in Study: ZDF-obese males Date of Birth: 17-Jun-4 Group 1 - RO H2O

More information

Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity

Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity Research article Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity Katharina Hopp, 1 Christopher J. Ward, 2 Cynthia J. Hommerding, 2 Samih H. Nasr, 3 Han-Fang

More information

CHRONIC KIDNEY DISEASE WHY WOMEN MAY BE AT RISK?

CHRONIC KIDNEY DISEASE WHY WOMEN MAY BE AT RISK? CHRONIC KIDNEY DISEASE WHY WOMEN MAY BE AT RISK? Dr. Judy A Geissler, DNP, APNP, FNP-BC, CNN Vascular Access Advanced Practice Provider Employer- Medical College of Wisconsin No financial disclosures Barbara

More information

Clinical characterization of polycystic kidney diseases in infants and children

Clinical characterization of polycystic kidney diseases in infants and children Clinical characterization of polycystic kidney diseases in infants and children Thesis Submitted for partial fulfillment of the M.Sc degree in Pediatrics Submitted by Ahmed Ibrahim Abulkhir Khayyal Under

More information

JINARC (tolvaptan) Patient/carer education brochure

JINARC (tolvaptan) Patient/carer education brochure JINARC (tolvaptan) Patient/carer education brochure This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side

More information

a) They are the most common cause of pediatric kidney failure. b) They are always symptomatic. c) They can be asymmetric.

a) They are the most common cause of pediatric kidney failure. b) They are always symptomatic. c) They can be asymmetric. Practice questions: 1. The paraxial mesoderm gives rise to somites. The structure of the somite a) is a loose mesenchymal sheet that will migrate toward the notochord. b) is an epithelial rosette with

More information

Tolvaptan in Polycystic Kidney Disease

Tolvaptan in Polycystic Kidney Disease Tolvaptan in Polycystic Kidney Disease Information for you Follow us on Twitter @NHSaaa Find us on Facebook at www.facebook.com/nhsaaa Visit our website: www.nhsaaa.net All our publications are available

More information

MTB-1 MEDIATED GENE REGULATION SHOWS BENEFICIAL EFFECTS IN DMD PATIENT CELLS AND MDX MICE

MTB-1 MEDIATED GENE REGULATION SHOWS BENEFICIAL EFFECTS IN DMD PATIENT CELLS AND MDX MICE targeting mitochondria. advancing human health. MTB-1 MEDIATED GENE REGULATION SHOWS BENEFICIAL EFFECTS IN DMD PATIENT CELLS AND MDX MICE PPMD 2016 Annual Connect Conference George Mulligan, PhD VP Translational

More information

Summary. 20 May 2014 EMA/CHMP/SAWP/298348/2014 Procedure No.: EMEA/H/SAB/037/1/Q/2013/SME Product Development Scientific Support Department

Summary. 20 May 2014 EMA/CHMP/SAWP/298348/2014 Procedure No.: EMEA/H/SAB/037/1/Q/2013/SME Product Development Scientific Support Department 20 May 2014 EMA/CHMP/SAWP/298348/2014 Procedure No.: EMEA/H/SAB/037/1/Q/2013/SME Product Development Scientific Support Department evaluating patients with Autosomal Dominant Polycystic Kidney Disease

More information

TR-469 Toxicology and Carcinogenesis Studies of AZT (CAS No ) and AZT/-Interferon A/D B6C3F1 Mice (Gavage Studies)

TR-469 Toxicology and Carcinogenesis Studies of AZT (CAS No ) and AZT/-Interferon A/D B6C3F1 Mice (Gavage Studies) (This document has been reformatted unchanged from the original document except for the bold emphasis editing by Stuart Thomson, Director, the Gaia Research Institute. S.T.) TR-469 Toxicology and Carcinogenesis

More information

Tolvaptan: a Possible Treatment for Autosomal Dominant Polycystic Kidney Disease

Tolvaptan: a Possible Treatment for Autosomal Dominant Polycystic Kidney Disease Pacific University CommonKnowledge School of Physician Assistant Studies Theses, Dissertations and Capstone Projects Fall 9-20-2013 Tolvaptan: a Possible Treatment for Autosomal Dominant Polycystic Kidney

More information

Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer This is a two-arm, randomized phase II trial for patients with BRAF mutant

More information

Total Kidney Volume (TKV) in Autosomal Dominant Polycystic Kidney Disease as model for biomarker qualification

Total Kidney Volume (TKV) in Autosomal Dominant Polycystic Kidney Disease as model for biomarker qualification Total Kidney Volume (TKV) in Autosomal Dominant Polycystic Kidney Disease as model for biomarker qualification Roslyn Simms NIHR Clinical Lecturer in Nephrology NIHR Clinical Trials Fellow Monday 23 rd

More information

ADPKD. Patient Forum. Questions, answers and discussions about living with ADPKD

ADPKD. Patient Forum. Questions, answers and discussions about living with ADPKD ADPKD Patient Forum Questions, answers and discussions about living with ADPKD 1 KEY ROLES OF HEALTHY KIDNEYS The kidneys filter approximately 200 liters of blood daily to remove water, waste and maintain

More information

A synergistic anti-obesity effect by a combination of capsinoids and cold temperature through the promotion of beige adipocyte biogenesis

A synergistic anti-obesity effect by a combination of capsinoids and cold temperature through the promotion of beige adipocyte biogenesis A synergistic anti-obesity effect by a combination of capsinoids and cold temperature through the promotion of beige adipocyte biogenesis Kana Ohyama, 1,2 Yoshihito Nogusa, 1 Kosaku Shinoda, 2 Katsuya

More information